Payment overview · 2025
General Payments
$1,046.16
54 reported records · 17 companies
Healthcare provider profile · identity verified
John N Odom, MD
Allopathic & Osteopathic Physicians|Family Medicine · MULLINS, SC · NPI 1003889387
Verified facts
What the public records show
CMS Open Payments records show John N Odom, MD received $1,046.16 in general payments during 2025 across 54 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $177.24 | 16.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.55 | 14.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $130.69 | 12.5% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $105.32 | 10.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.43 | 8.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.90 | 6.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.09 | 6.4% | 3 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $40.56 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.63 | 3.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.81 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.90 | 2.8% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $22.81 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.38 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.69 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.97 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.61 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.58 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,046.16 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $177.24 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $105.32 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.43 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.80 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $71.90 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $71.90 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.09 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.53 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.90 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.90 | 2 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 364 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 174 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
138 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
364 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
364 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
174 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 969 | 255 |
| Atorvastatin Calcium | Atorvastatin Calcium | 755 | 193 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 665 | 157 |
| Gabapentin | Gabapentin | 551 | 131 |
| Omeprazole | Omeprazole | 491 | 124 |
| Furosemide | Furosemide | 464 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 119 |
| Losartan Potassium | Losartan Potassium | 388 | 98 |
| Jardiance | Empagliflozin | 364 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 84 |
| Lisinopril | Lisinopril | 333 | 83 |
| Metformin Hcl Er | Metformin Hcl | 318 | 87 |
| Metformin Hcl | Metformin Hcl | 311 | 86 |
| Pravastatin Sodium | Pravastatin Sodium | 307 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 63 |
| Meloxicam | Meloxicam | 241 | 47 |
| Eliquis | Apixaban | 239 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 237 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 55 |
| Sertraline Hcl | Sertraline Hcl | 220 | 50 |
| Alprazolam | Alprazolam | 219 | 41 |
| Potassium Chloride | Potassium Chloride | 218 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 31 |
| Trazodone Hcl | Trazodone Hcl | 205 | 47 |
| Allopurinol | Allopurinol | 204 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 30 |
| Ezetimibe | Ezetimibe | 191 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 48 |
| Tramadol Hcl | Tramadol Hcl | 188 | 41 |
| Famotidine | Famotidine | 185 | 52 |
| Mirtazapine | Mirtazapine | 184 | 44 |
| Carvedilol | Carvedilol | 177 | 49 |
| Celecoxib | Celecoxib | 175 | 39 |
| Mounjaro | Tirzepatide | 174 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 167 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 47 |
| Prednisone | Prednisone | 156 | 122 |
| Pregabalin | Pregabalin | 154 | 32 |
| Valsartan | Valsartan | 154 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 36 |
| Linzess | Linaclotide | 138 | 40 |
| Simvastatin | Simvastatin | 136 | 33 |
| Buspirone Hcl | Buspirone Hcl | 133 | 30 |
| Spironolactone | Spironolactone | 133 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 123 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 122 | 28 |
| Irbesartan | Irbesartan | 119 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 37 |
| Ozempic | Semaglutide | 115 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 112 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 110 | 85 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 27 |
| Donepezil Hcl | Donepezil Hcl | 106 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 101 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 20 |
| Fluconazole | Fluconazole | 95 | 33 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 93 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 22 |
| Benazepril Hcl | Benazepril Hcl | 91 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 90 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 43 |
| Meclizine Hcl | Meclizine Hcl | 86 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 17 |
| Montelukast Sodium | Montelukast Sodium | 76 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 17 |
| Clonazepam | Clonazepam | 75 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 14 |
| Januvia | Sitagliptin Phosphate | 71 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 19 |
| Estradiol | Estradiol | 67 | 12 |
| Nifedipine Er | Nifedipine | 67 | 17 |
| Sucralfate | Sucralfate | 66 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 52 |
| Lovastatin | Lovastatin | 63 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 22 |
| Trulicity | Dulaglutide | 63 | 11 |
| Glimepiride | Glimepiride | 61 | 17 |
| Cefdinir | Cefdinir | 60 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 18 |
| Warfarin Sodium | Warfarin Sodium | 58 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 53 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Fenofibrate | Fenofibrate,micronized | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 16 |
| Memantine Hcl Er | Memantine Hcl | 51 | suppressed |
| Bumetanide | Bumetanide | 50 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | 11 |
| Finasteride | Finasteride | 49 | 16 |
| Klor-Con M20 | Potassium Chloride | 48 | 18 |
| Mupirocin | Mupirocin | 47 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Temazepam | Temazepam | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Atenolol | Atenolol | 42 | 14 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 35 | 11 |
| Azithromycin | Azithromycin | 35 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 13 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Colchicine | Colchicine | 32 | 13 |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Hydrocortisone | Hydrocortisone | 31 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 16 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,046.16 · 54 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, CYGNUS DUAL, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error